Core Viewpoint - The strategic cooperation agreement between Zhongsheng Beikong Biotechnology (08247) and Xiaoshou Medical aims to enhance the capacity of grassroots medical services and promote the distribution of quality medical resources [1] Group 1: Capital and Strategic Collaboration - The company plans to make a strategic investment in Xiaoshou Medical to establish a long-term stable partnership and explore innovative development models in the grassroots medical market [2] Group 2: Business and Resource Complementation - The company will leverage its advantages in in vitro diagnostics (IVD) products and R&D capabilities, combined with Xiaoshou Medical's nationwide grassroots medical channel network and digital platform, to deliver biochemical, immunological, and POCT products directly to grassroots medical institutions [3] - A joint working group will be established to enhance data insights, product development, and supply chain optimization while developing customized products and "smart testing solutions" suitable for grassroots medical scenarios [3] Group 3: Ecosystem and Value Co-Creation - The collaboration will integrate various resources such as equipment, reagents, operations, and data to provide one-stop testing service solutions for regional medical communities and chain clinics, thereby improving the overall testing capabilities and operational efficiency of grassroots medical institutions [4] - The cooperation will be implemented in phases, starting with strategic pilot verification and gradually expanding to large-scale implementation, while exploring deeper collaboration at the industrial and capital levels [4] - The board believes that this strategic cooperation will help the company integrate quality R&D capabilities with digital channel resources, accelerating the penetration of products and services into grassroots medical institutions, aligning with national initiatives to enhance the grassroots medical system and the "Healthy China" strategy [4]

Group 1 - The core viewpoint of the announcement is the strategic cooperation agreement between China National Pharmaceutical Group (中生北控生物科技) and Guangdong Xiaoshou Medical Technology, aimed at enhancing grassroots medical services and resource allocation [1][2][3] Group 2 - The cooperation will involve capital and strategic synergy, with the company planning to make a strategic investment in Xiaoshou Medical to establish a long-term partnership and explore innovative development models in the grassroots medical market [1][2] - The collaboration will leverage the company's strengths in in vitro diagnostics (IVD) and Xiaoshou Medical's extensive grassroots medical network and digital platform to deliver biochemical, immunological, and POCT products directly to grassroots medical institutions [2] - The partnership aims to create a one-stop testing service solution for regional medical communities and chain clinics by integrating various resources, thereby improving the overall testing capabilities and operational efficiency of grassroots medical institutions [3]